In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?

被引:16
|
作者
Kuentz, Martin [1 ]
Imanidis, Georgios [1 ,2 ]
机构
[1] Univ Appl Sci & Arts NW Switzerland, Inst Pharmaceut Technol, CH-4132 Muttenz, Switzerland
[2] Univ Basel, Dept Pharmaceut Sci, CH-4056 Basel, Switzerland
关键词
Poorly soluble drugs; Oral drug absorption; Bioavailability; Amorphous; Molecular modeling; In silico; PRECIPITATION INHIBITORS; BETA-CYCLODEXTRIN; ORAL ABSORPTION; MELTING-POINTS; DISSOLUTION; BEHAVIOR; IMPROVE;
D O I
10.1016/j.ejps.2012.11.015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oral delivery of poorly water-soluble compounds is often a substantial challenge. Once a drug candidate is selected, it is desirable to predict, based on chemical structure, which formulation technology has the highest potential to enhance drug solubility and absorption. Due to the importance of amorphous drug formulations, this work aimed at calculating the solubility ratio of amorphous and crystalline drug using in silico methods only. Molecular modeling together with multivariate methods was employed and a particular aim was to find simple structure-based rules for the technology selection of amorphous drug formulations. As a result, calculated estimates for reference compounds were generally higher than experimentally obtained amorphous solubility ratios; however, the rank order of the values revealed a significant correlation (p = 0.036). Subsequently, a set of 56 neutral poorly water-soluble compounds resulted in a good partial least square model with R-2 of 0.803. Most important for the amorphous solubility ratio was molecular weight, number of hydrogen bond acceptors, melting point, number of torsional bonds and polar surface area. By considering the Lipinsky rules, we proposed suitable ranges of these molecular predictors with respect to selecting promising amorphous drug formulations. Such structure-based guidance can help in early formulation development of challenging drug candidates, thereby leading to substantial cost savings. However, there is certainly more experimental research needed to finally assess how broadly the presented concepts can be applied. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:554 / 562
页数:9
相关论文
共 7 条
  • [1] Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool
    Zeng, Shaogao
    Dou, Wenyuan
    Li, Manna
    Zhou, Yang
    Guo, Jiehuang
    Zhao, Nan
    Huang, Hong
    Zhou, Qiaoli
    Hu, Wenhui
    Ma, Yanfang
    Zhao, Xin
    Xie, Hui
    CHEMMEDCHEM, 2020, 15 (16) : 1608 - 1617
  • [2] ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?
    Hou, Tingjun
    Wang, Junmei
    Zhang, Wei
    Xu, Xiaojie
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2007, 47 (02) : 460 - 463
  • [3] Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery
    Shi, Jian
    Zha, Weibin
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (01) : 135 - 137
  • [4] Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery
    Jian Shi
    Weibin Zha
    European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44 : 135 - 137
  • [5] Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 1. Aqueous solubility
    Liu, RF
    So, SS
    JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2001, 41 (06): : 1633 - 1639
  • [6] Computational prediction of drug solubility in water-based systems: Qualitative and quantitative approaches used in the current drug discovery and development setting
    Bergstrom, Christel A. S.
    Larsson, Per
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2018, 540 (1-2) : 185 - 193
  • [7] Basic approach to optimize the small drug seeds with minimized CV risks on the early stage of drug discovery by using small molecule-based in silico models for prediction of hERG/Nav1.5 inhibitions
    Dodo, Tetsushi
    Kawada, Megumi Ikemori
    Yu, Melvin
    Yoshinaga, Takashi
    Inoue, Atsushi
    Sawada, Kohei
    TOXICOLOGY LETTERS, 2014, 229 : S159 - S159